Literature DB >> 2467128

Block of heart calcium channels by amlodipine: influence of drug charge on blocking activity.

R S Kass1, J P Arena, D DiManno.   

Abstract

Changes in pH0 were used to to vary the ratio of neutral to ionized amlodipine (acid dissociation constant = 10(-8.6). The behavior of neutral and charged drug blockade of calcium channel current (ICa) was tested in the context of the modulated receptor hypothesis. ICa was recorded at room temperature from enzymatically isolated guinea pig ventricular cells using the whole-cell arrangement of the patch-clamp technique. When amlodipine was predominantly charged (pH0 = 7.4), trains of pulses that induced multiple channel openings enhanced block, but inhibition of ICa was also promoted by depolarizing changes in holding potential. Neutral amlodipine (pH0 = 10.0), blocked ICa at depolarized membrane potentials without channel openings. This form of the drug resembled other previously described neutral dihydropyridine (DHP) blockers in its voltage dependence. Recovery from block by ionized drug molecules was very slow and incomplete, whereas block by neutral molecules was always reversible at hyperpolarized membrane potentials. We conclude that amlodipine, like other DHP calcium channel blockers, preferentially blocks calcium channels in depolarized cells. At pH0 7.4 amlodipine molecules gain access to the DHP receptor more readily when channels open, but channel openings are not required for this interaction. Recovery from block by ionized drug is almost irreversible, suggesting that channel openings are needed for this process or that the ionized drug stabilizes the calcium channel in a nonconducting state.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467128     DOI: 10.1097/00005344-198812007-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 2.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.

Authors:  Susanne Wirtz; Stefan Herzig
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

4.  Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.

Authors:  Thomas J Dennison; Julian C Smith; Raj K Badhan; Afzal R Mohammed
Journal:  Drug Des Devel Ther       Date:  2017-03-16       Impact factor: 4.162

5.  Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination.

Authors:  Farhan Aslam; Attiya Haque; Veronica Lee; Joanne Foody
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.